AOCNP Hematologic Malignancies 4

Question 1

A patient with CLL is found to have del(17p) on FISH testing. Which targeted therapy is the preferred first-line agent for this high-risk mutation?

Accepted Answer

Ibrutinib

Answer

Del(17p) CLL is resistant to chemoimmunotherapy due to loss of p53; ibrutinib (a BTK inhibitor) is preferred first-line.

Question 2

Which of the following is the most common cytogenetic abnormality in multiple myeloma that confers a standard-risk prognosis?

Accepted Answer

Hyperdiploidy

Answer

Hyperdiploidy, typically involving odd-numbered chromosomes, is the most common cytogenetic finding in myeloma and is associated with standard risk.

Question 3

A patient on venetoclax for AML develops tumor lysis syndrome (TLS). Which lab finding is NOT a feature of TLS?

Accepted Answer

Hypercalcemia

Answer

TLS causes hypocalcemia (not hypercalcemia) because phosphate released from lysed cells binds calcium, lowering serum levels.

Question 4

A 45-year-old with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieves complete remission after CAR-T cell therapy. What is the most serious early toxicity to monitor for in the first 2 weeks?

Accepted Answer

Cytokine release syndrome (CRS)

Answer

CRS is the most common and potentially life-threatening early toxicity after CAR-T therapy, caused by massive cytokine release from activated T cells.

Question 5

In the revised International Prognostic Index (R-IPI) for DLBCL, which of the following is NOT one of the five adverse prognostic factors?

Accepted Answer

Bone marrow involvement

Answer

The R-IPI uses age >60, elevated LDH, ECOG PS >1, Ann Arbor stage III/IV, and >1 extranodal site; bone marrow involvement per se is not a standalone factor.

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP Hematologic Malignancies 4